CTOs on the Move

Magellan Medicaid Administration

www.magellanmedicaid.com

 
Magellan Medicaid Administration is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

EyeWatch LIVE

EyeWatch Live is a company that provides a virtual nurse monitoring system that combines artificial intelligence (AI) with human intelligence (HI) to identify unwanted activity and prevent falls before they occur.

Zanthion

Zanthion protects the elderly from harm, automatically notifies near responders to avoid catastrophic damage, offers solace until help arrives, predicts future needs through artificial intelligence, and connects seniors to the world and their community. Zanthion is a pioneer in changing our social environment with future vision and use case (solution based) systems that improve the world based on open source, transparent, crowdsourced economic mechanisms that accurately assess what happened, inform the correct resources that the event has occurred, provide resources to the problem efficiently, and keep track of the efficiency of fixing the non-conformity. Our platform is generic and it is open. We embrace a responsible future.

Texas Health Network

Texas Health Network is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Austin, TX. To find more information about Texas Health Network, please visit www.tmhp.com

ICT For Health

ICT For Health is a Crossroads, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Geron

We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.